Current CDC surveillance shows no active Level 4 Travel Health Notices, with all ongoing alerts limited to Levels 1–3 for conditions such as Ebola Bundibugyo virus disease in Uganda and the Democratic Republic of the Congo, malaria in Mayotte, and chikungunya in Mauritius. These reflect moderate transmission risks addressable through standard precautions, consistent with historical patterns where Level 4 designations occur only during uncontrolled outbreaks lacking effective mitigation. Recent model consensus and case data through early June 2026 indicate no rapid escalation thresholds met for any pathogen. Trader sentiment favoring “No” by year-end aligns with the absence of novel high-severity clusters or surveillance signals that would trigger the extreme-risk criteria required for a Level 4 notice.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado¿Los CDC emiten una advertencia de Nivel 4 antes del 31 de diciembre?
¿Los CDC emiten una advertencia de Nivel 4 antes del 31 de diciembre?
Sí
$71,851 Vol.
$71,851 Vol.
31 dic 2026
Sí
$71,851 Vol.
$71,851 Vol.
31 dic 2026
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Current CDC surveillance shows no active Level 4 Travel Health Notices, with all ongoing alerts limited to Levels 1–3 for conditions such as Ebola Bundibugyo virus disease in Uganda and the Democratic Republic of the Congo, malaria in Mayotte, and chikungunya in Mauritius. These reflect moderate transmission risks addressable through standard precautions, consistent with historical patterns where Level 4 designations occur only during uncontrolled outbreaks lacking effective mitigation. Recent model consensus and case data through early June 2026 indicate no rapid escalation thresholds met for any pathogen. Trader sentiment favoring “No” by year-end aligns with the absence of novel high-severity clusters or surveillance signals that would trigger the extreme-risk criteria required for a Level 4 notice.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Mercado abierto: Jan 19, 2026, 3:15 PM ET
Volumen
$71,851Fecha de finalización
31 dic 2026Mercado abierto
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.Current CDC surveillance shows no active Level 4 Travel Health Notices, with all ongoing alerts limited to Levels 1–3 for conditions such as Ebola Bundibugyo virus disease in Uganda and the Democratic Republic of the Congo, malaria in Mayotte, and chikungunya in Mauritius. These reflect moderate transmission risks addressable through standard precautions, consistent with historical patterns where Level 4 designations occur only during uncontrolled outbreaks lacking effective mitigation. Recent model consensus and case data through early June 2026 indicate no rapid escalation thresholds met for any pathogen. Trader sentiment favoring “No” by year-end aligns with the absence of novel high-severity clusters or surveillance signals that would trigger the extreme-risk criteria required for a Level 4 notice.
This market will resolve to "Yes" if the CDC issues a Level 4 (“Avoid All Travel”) Travel Health Notice for any disease by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
A Level 4 notice listed for any amount of time during this market’s timeframe will suffice for a "Yes" resolution.
The primary resolution source for this market will be the CDC’s official Travel Health Notices page (https://wwwnc.cdc.gov/travel/notices); however, a consensus of credible reporting will also be used.
Volumen
$71,851Fecha de finalización
31 dic 2026Mercado abierto
Jan 19, 2026, 3:15 PM ETResolver
0x65070BE91...Current CDC surveillance shows no active Level 4 Travel Health Notices, with all ongoing alerts limited to Levels 1–3 for conditions such as Ebola Bundibugyo virus disease in Uganda and the Democratic Republic of the Congo, malaria in Mayotte, and chikungunya in Mauritius. These reflect moderate transmission risks addressable through standard precautions, consistent with historical patterns where Level 4 designations occur only during uncontrolled outbreaks lacking effective mitigation. Recent model consensus and case data through early June 2026 indicate no rapid escalation thresholds met for any pathogen. Trader sentiment favoring “No” by year-end aligns with the absence of novel high-severity clusters or surveillance signals that would trigger the extreme-risk criteria required for a Level 4 notice.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes